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Summary
Background The population infected with HIV is getting older and these people will increasingly develop age-related 
non-communicable diseases (NCDs). We aimed to quantify the scale of the change and the implications for HIV care 
in the Netherlands in the future.
Methods We constructed an individual-based model of the ageing HIV-infected population, which followed patients 
on HIV treatment as they age, develop NCDs—including cardiovascular disease (hypertension, hypercholesterolaemia, 
myocardial infarctions, and strokes), diabetes, chronic kidney disease, osteoporosis, and non-AIDS malignancies—
and start co-medication for these diseases. The model was parameterised by use of data for 10 278 patients from the 
national Dutch ATHENA cohort between 1996 and 2010. We made projections up to 2030.
Findings Our model suggests that the median age of HIV-infected patients on combination antiretroviral therapy 
(ART) will increase from 43·9 years in 2010 to 56·6 in 2030, with the proportion of HIV-infected patients aged 
50 years or older increasing from 28% in 2010 to 73% in 2030. In 2030, we predict that 84% of HIV-infected patients 
will have at least one NCD, up from 29% in 2010, with 28% of HIV-infected patients in 2030 having three or more 
NCDs. 54% of HIV-infected patients will be prescribed co-medications in 2030, compared with 13% in 2010, with 
20% taking three or more co-medications. Most of this change will be driven by increasing prevalence of 
cardiovascular disease and associated drugs. Because of contraindications and drug–drug interactions, in 2030, 40% 
of patients could have complications with the currently recommended ﬁ rst-line HIV regimens.
Interpretation The proﬁ le of patients in the Netherlands infected with HIV is changing, with increasing numbers of 
older patients with multiple morbidities. These changes mean that, in the near future, HIV care will increasingly need to 
draw on a wide range of medical disciplines, in addition to evidence-based screening and monitoring protocols to ensure 
continued high-quality care. These ﬁ ndings are based on a large dataset of HIV-infected patients in the Netherlands, but 
we believe that the overall patterns will be repeated elsewhere in Europe and North America. The implications of such a 
trend for care of HIV-infected patients in high-burden countries in Africa could present a particular challenge.
Funding Medical Research Council, Bill & Melinda Gates Foundation, Rush Foundation, and Netherlands Ministry of 
Health, Welfare and Sport.
Copyright © Smit et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
More than 30 years after HIV started to spread, and 
almost 20 years after combination antiretroviral therapy 
(ART) became available, the proﬁ le of the HIV epidemic 
in Europe is changing. HIV treatment has improved 
substantially since the introduction of ART.1 Improved 
eﬃ  cacy of ART to suppress HIV replication has reduced 
the mortality of HIV-infected patients on treatment.2 This 
reduction in mortality has transformed HIV into a long-
term chronic illness for many patients, characterised by 
an ageing HIV-infected population who are increasingly 
aﬀ ected by age-related non-com municable diseases 
(NCDs).3 The increasing prevalence of NCDs complicates 
treatment and care for HIV-infected patients.3,4 Treatment 
for NCDs can cause problems related to polypharmacy—
coadministration of multiple drugs in addition to HIV 
drugs—leading to increased pill burden,3,4 potential drug–
drug interactions and adverse eﬀ ects, and loss of 
treatment eﬃ  cacy and subsequent virological 
breakthrough. Results from several studies have shown 
that people infected with HIV might have a higher 
prevalence and earlier age of onset for many NCDs than 
do age-matched uninfected individuals.5–7 This eﬀ ect has 
been shown for several comorbidities, including 
cardiovascular disease,8,9 non-AIDS malignancies,10 liver 
and kidney disease,11 and osteoporosis.12,13 
A Dutch prospective cohort study6 noted that prevalence 
of hypertension, cardiovascular and peripheral vascular 
disease, and impaired renal function (but not metabolic, 
pulmonary, bone, and malignant disease) was 
signiﬁ cantly increased in HIV-infected participants 
compared with uninfected controls, with no reported 
diﬀ erence by sex. In 2014, a study of the Veterans Ageing 
Cohort reported that, although HIV-infected adults had 
increased risk of age-related NCDs, they occurred at 
similar ages in uninfected individuals.7 Long-term use of 
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antiretroviral drugs, sustained HIV-associated immune 
activation, and chronic inﬂ ammation have all been 
reported to be associated with increased risk of comorbid 
disease.5,6,13–15 Although concentrations of some bio-
markers of inﬂ ammation and immune activation in HIV-
infected patients return to those of uninfected individuals 
within the ﬁ rst year after ART-induced viral suppression, 
several markers remain unusually high.16 The future scale 
of the associated diseases and conditions and how this 
will aﬀ ect HIV care remain unclear. Such an evaluation is 
important to address future challenges, develop evidence-
based changes to clinical guidelines, and ensure 
continued high-quality care.
We constructed an individual-based model, which 
represented the onset of NCDs, ageing, polypharmacy, 
and drug–drug interactions, and parameterised it with 
data from the Dutch ATHENA cohort.17 We used the 
model to project the future of the ageing HIV-infected 
population in the Netherlands and to identify the 
implications of the predictions and actions needed to 
address these coming trends.
Methods
Data source
We developed the model for the Netherlands using data 
from the ATHENA cohort. ATHENA is a national 
observational cohort that has collected data from all HIV-
infected patients in clinical care in the Netherlands since 
1996. The design of this cohort has been described 
previously.17 Clinical, biological, and immunological data 
for HIV-infected patients are collected at entry and at 
each follow-up visit.
We included patients from the ATHENA cohort in the 
analysis if they were aged 18 or older, infected with HIV-1, 
antiretroviral drug naive, and diagnosed with HIV on or 
after Jan 1, 1996. We excluded women who were known 
to have been pregnant during follow-up because of the 
treatment changes that occur because of pregnancy and 
the eﬀ ect this would have on the model’s predictions of 
drug–drug interactions. In total, we excluded 
1005 pregnant women (9·7%) from the analysis out of 
the total study population. We analysed the data up to 
and including Dec 31, 2010, with the data encompassing 
10 278 individuals. All values for parameters were based 
on data from patients on ART.
Most of the study population used for model 
parameterisation were Dutch men who have sex with 
men (table 1). The three most prevalent NCDs were 
hypercholesterolaemia, hypertension, and chronic 
kidney disease. The epidemic in the Netherlands is well 
documented,18,19 and in 2010, mortality was 0·8% and the 
number of AIDS diagnoses was 0·3%. Similar to most 
other countries in Europe and North America, the 
epidemic in the Netherlands is concentrated in men who 
have sex with men. The prevalence of HIV in the 
Netherlands is 0·2%, which is similar to that of the UK 
(0·2%) and lower than that of the USA (0·6%).20
Model
We constructed an individual-based model of the 
ageing HIV-infected population in the Netherlands 
(ﬁ gure 1). The appendix contains technical details of 
how the model was constructed. The model follows 
HIV-infected patients from the start of treatment until 
death or the end of the model simulation in 2030, as 
they age, develop NCDs, start co-medication for these 
disorders, and how co-medications aﬀ ect HIV 
treatment. The model also captures the interactions 
between NCDs (ﬁ gure 1). The choice of factors modelled 
was based on incorporation of the major age-related 
NCDs that will play an important part in future clinical 
care for HIV and for which the available data were 
suﬃ  cient for predictions to be made—ie, diabetes 
mellitus, hypertension, hyper cholestero laemia, osteo-
porosis, chronic kidney disease, strokes, myo cardial 
infarctions, and non-AIDS mali gnancy. We validated 
model performance by use of out-of-sample prediction 
checks for the period of 2011–13 in the data, in which 
we set aside the most recent ATHENA data to compare 
with our predictions (appendix).
We probabilistically assigned demographic factors to 
patients upon entry into the model in accordance with 
frequency distributions from ATHENA cohort data. We 
ATHENA cohort population 
(n=10 278)
Sex
Male 8586 (84%)
Female 1692 (16%)
Age in 2010, years 44·5 (10·4)
Transmission
Men who have sex with men 6040 (59%)
Heterosexual 3300 (32%)
Injecting drug user 208 (2%)
Other or unknown 730 (7%)
Region of origin
Netherlands 5967 (58%)
Sub-Saharan Africa 1628 (16%)
Europe 855 (8%)
Other 1828 (18%)
Prevalence of NCD
Diabetes 578 (6%)
Hypertension 2379 (23%)
Hypercholesterolaemia 2502 (24%)
Malignancies* 765 (7%)
Myocardial infarction* 216 (2%)
Osteoporosis 829 (8%)
Chronic kidney disease 1399 (14%)
Stroke* 156 (2%)
Data are n (%) or median (SD). NCD=non-communicable disease. *Deﬁ ned as the 
number of patients ever diagnosed with an NCD in the study population.
Table 1: Demographic characteristics of the ATHENA cohort used for 
model parameterisation 
See Online for appendix
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simulated the rate of future entry into care using a 
compartmental model of the HIV epidemic by 
extrapolating past trends in HIV diagnosis and ART 
initiation rates from observational data (appendix). The 
main results assume a medium incidence scenario 
whereby incidence decreases gradually in the coming 
years, but alternative analyses for diﬀ erent future 
trajectories in incidence are described in the appendix. 
The model makes an implicit assumption that time from 
infection to treatment initiation is constant. We took 
parameters to deﬁ ne cause-speciﬁ c death rates by age and 
sex from a large multicohort study by the Data Collection 
on Adverse Events of Anti-HIV drugs study group.21
Where possible, we deﬁ ned all NCDs in accordance 
with European AIDS Clinical Society (EACS) clinical and 
laboratory guidelines for diagnosis.22 We based deﬁ nitions 
of myocardial infarction, stroke, osteoporosis, and non-
AIDS malignancies on information registered in patients’ 
ﬁ les. We deﬁ ned chronic kidney disease as glomerular 
ﬁ ltration rate less than 60 mL/min per 1·73 m² using the 
Cockcroft-Gault equation, conﬁ rmed after 3 months or 
later,23 hyper tension, and hyper cholestero laemia on blood 
pressure measurements and laboratory results. For 
diabetes, we used both registry data and use of antidiabetic 
drugs to deﬁ ne diabetes status. Where possible, we used 
pathology reports to conﬁ rm diagnosis of any non-AIDS 
malignancy.23 Malignancies included all cancers, except 
AIDS-deﬁ ning cancers, precancerous stages of anal and 
cervical cancer, basal cell carcinoma, and squamous cell 
carcinoma of the skin.
We modelled age-and-sex-speciﬁ c prevalence of 
existing NCDs among patients already in care in 2010 
(when the model starts) using observational ATHENA 
data. We simulated incidence of new NCDs by using 
observational estimates of the age-and-sex-speciﬁ c 
incidence per 1000 person-years of follow-up from the 
ATHENA cohort (table 2). The propensity for one 
disorder to be associated with increased risk for 
development of another, through common causal 
pathways, was incorporated into the model, with 
parameters to deﬁ ne these pathways based on both 
ATHENA data and an in-depth literature review (ﬁ gure 1, 
table 3). Where patients had two or more NCDs that 
could aﬀ ect the development of another NCD, we 
calculated parameters as the mean of the largest factor 
and the product of the factors. To simulate NCD burden 
in the age-and-sex-matched HIV-negative population, we 
reran the model with the relative reduced risk for chronic 
kidney disease and cardiovascular disease reported by 
the AGEhIV study.6 The AGEhIV study has compared 
prevalence and incidence of a broad range of NCDs in 
HIV-infected individuals and age-matched uninfected 
controls since 2010.6
The choice of co-medication in the model was restricted 
to the most commonly prescribed co-medications in HIV-
infected patients in the Netherlands, and excludes co-
medication contraindicated for HIV-infected patients on 
High blood 
pressure 
High
cholesterol 
Renal
insuﬃciency Diabetes
Malignancy
Comedication
ART
Osteoporosis
Heart disease
(myocardial
infarction
and stroke)
MortalityAge
 Figure 1: Schematic of the model of an ageing HIV-infected population
The model follows HIV-infected patients from the start of treatment until death or last year of model (2030). The 
model simulates how, over time, HIV-infected patients age, develop comorbidities, start co-medication for these 
conditions, and how these co-medications aﬀ ect HIV treatment. The dashed square shows the comorbidities and 
interactions included in the model. Patients developed comorbidities as a function of age and sex. Comedication is 
prescribed on the basis of the comorbidities a patient has, which in turn aﬀ ect drug–drug interactions with 
HIV treatment (ART). Mortality risk is aﬀ ected by both age and the number and type of comorbidity and is 
simulated for patients on ART. ART=antiretroviral therapy.
Incidence in men per 
1000 person-years
Incidence in women per 
1000 person-years
Diabetes mellitus
<30 years 0·5 (0·1–2·0) 3·0 (1·5–5·3)
30–40 years 2·5 (1·9–3·3) 3·8 (2·6–5·3)
40–50 years 4·4 (3·7–5·2) 5·7 (3·9–8·1)
50–60 years 7·2 (5·9–8·8) 7·2 (3·6–12·9)
≥60 years 11·7 (9·0–15·1) 13·6 (6·2–25·8)
Hypercholesterolaemia
<30 years 25·8 (20·0–32·7) 36·5 (25·8–50·1)
30–40 years 34·3 (31·1–37·7) 38·0 (31·4–45·6)
40–50 years 59·2 (55·4–63·1) 50·9 (42·4–60·6)
50–60 years 82·6 (76·0–89·5) 116·4 (94·7–141·5)
≥60 years 117·3 (104·6–131·2) 130·8 (98·9–170·0)
Hypertension
<30 years 19·3 (14·3–25·4) 20·1 (13·2–31·9)
30–40 years 25·8 (23·0–28·8) 18·8 (14·2–24·5)
40–50 years 39·7 (36·5–43·0) 43·4 (35·2–52·9)
50–60 years 57·8 (52·1–63·9) 58·1 (41·3–79·5)
≥60 years 72·3 (61·8–84·1) 69·5 (45·4–101·8)
Malignancy
<30 years 1·4 (0·4–3·2) 0·3 (0·0–1·5)
30–40 years 2·3 (1·7–3·1) 1·9 (1·1–3·1)
40–50 years 5·1 (4·3–6·0) 5·2 (3·5–7·5)
50–60 years 9·6 (8·1–11·3) 6·5 (3·1–11·9)
≥60 years 18·5 (15·0–22·6) 9·9 (4·0–20·4)
(Table 2 continues on next page)
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ART in accordance with European guidelines.22 Co-
medications include diabetes drugs (metformin, insulin, 
and the sulfonylurea derivatives glibenclamide, gliclazide, 
glipizide, and tolbutamide); alendronic acid, vitamin D, 
and calcium supplements for osteoporosis; and 
angiotensin-converting enzyme inhibitors (captopril, 
enalapril, and lisinopril), β blockers (atenolol and 
metoprolol), calcium channel blockers (amlodipine, 
nifedipine, and verapamil), diuretics (bumetanide, 
furosemide, and hydrochlorothiazide), and statins 
(atorvastatin, pravastatin, and rosuvastatin) for cardio-
vascular disease.
The model incorporated the fact that existing guidelines 
in the Netherlands do not recommend any speciﬁ c treat-
ment for chronic kidney disease, except renal replace ment 
therapy for end stage chronic kidney disease (not 
modelled).22 To capture long-term burden of poly pharmacy 
and drug–drug interactions, we modelled only long-term 
treatment of NCDs. Consequently, we did not include the 
treatment of malignancies. Model parameters for co-
medication accounted for the fact that not all patients with 
each NCD received treatment, and were based on current 
prescribing practices in the Netherlands in accordance 
with the ATHENA data. The model assumed that current 
prescribing practices would remain the same in the future.
We quantiﬁ ed drug–drug interactions with the HIV 
Drug Interaction chart from the University of Liverpool, 
and con traindications between recommended ﬁ rst-line 
ART and NCDs were based on EACS guidelines.22 The 
EACS-recommended regimens (as of October, 2013) 
consisted of a backbone of tenofovir/emtricitabine or 
abacavir/lamivudine combined with either efavirenz, 
rilpivirine, raltegravir or ritonavir-boosted atzanavir, 
darunavir, or lopinavir.22
Role of funding source
The funder of the study had no role in study design, data 
collection, data analysis, data inter pretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
The model predicts that the median age of patients 
receiving treatment for HIV will increase from 43·9 years 
in 2010 to 56·6 years in 2030. The proportion of patients 
older than 50 years is predicted to increase from 28% in 
2010 to 73% in 2030, while the proportion of patients aged 
60 years or older will increase from 8% to 39% and the 
proportion aged 70 years or older will increase from 8% to 
12% (ﬁ gure 2). Even if patients starting ART had exactly 
the same average age as those in 2010, the median age in 
2030 would still be 55·7 years. If incidence declined more 
rapidly or slowly than expected, the median age in 2030 
would vary between 55·3 and 56·9 years (appendix).
As a result of the ageing HIV-infected population, the 
number of HIV-infected patients in the Netherlands with 
at least one NCD is projected to increase from 29% in 
2010 to 84% in 2030 (ﬁ gure 3). The number of patients 
with three or more NCDs is expected to increase from 
0·3% in 2010 to 28% of patients in clinical care in 2030. 
In 2030, only 16% of HIV-infected patients will not have 
any of the NCDs investigated (ﬁ gure 3). Sensitivity 
analysis that varied the incidence rates of NCDs did not 
materially aﬀ ect the overall patterns of increasing burden 
of NCDs in patients on ART, with lower rates tending to 
result in a slightly reduced burden of NCDs in 2030 and 
increased rates resulting in increased burden of NCDs 
compared with the projections presented here.
The proﬁ le of NCD burden is higher than is expected for 
the HIV-uninfected population with the same age structure 
and sex ratio (ﬁ gure 3). Simulations for both populations 
show that in 2030, 27% of HIV-infected patients are 
expected to have three or more NCDs, compared with 19% 
of HIV-uninfected individuals (ﬁ gure 3).
The increasing burden of NCDs will be driven by a 
steep increase in prevalence of cardiovascular disease, 
diabetes, and malignancies. In 2010, 19% of HIV-
Incidence in men per 
1000 person-years
Incidence in women per 
1000 person-years
(Continued from previous page)
Myocardial infarction
<30 years 0·0 (0·0–1·2) 0·0 (0·0–1·1)
30–40 years 0·7 (0·4–1·3) 0·5 (0·1–1·4)
40–50 years 2·8 (2·2–3·5) 0·9 (0·3–2·2)
50–60 years 5·6 (4·4–7·0) 0·0 (0·0–2·4)
≥60 years 8·9 (6·5–12·0) 7·5 (2·4–17·5)
Osteoporosis
<30 years 0·4 (0·0–2·2) 0·7 (0·1–2·5)
30–40 years 0·8 (0·4–1·5) 0·5 (0·1–1·3)
40–50 years 2·6 (2·0–3·4) 2·9 (1·6–4·8)
50–60 years 3·7 (2·7–4·9) 10·9 (6·1–17·9)
≥60 years 5·8 (3·8–8·3) 16·5 (7·9–30·4)
Chronic kidney disease
<30 years 2·8 (1·1–5·7) 2·4 (1·0–5·0)
30–40 years 3·5 (2·6–4·7) 2·1 (1·2–3·6)
40–50 years 4·7 (3·8–5·6) 6·2 (4·2–8·9)
50–60 years 8·4 (6·8–10·1) 14·8 (9·0–22·8)
≥60 years 17·7 (14·1–21·9) 11·4 (4·6–23·4)
Stroke
<30 years 1·0 (0·2–2·9) 0·6 (0·1–2·1)
30–40 years 0·9 (0·5–1·5) 1·2 (0·5–2·3)
40–50 years 1·4 (1·0–1·9) 1·9 (0·9–3·5)
50–60 years 3·2 (2·4–4·3) 2·7 (0·7–6·8)
≥60 years 7·4 (5·2–10·2) 7·4 (2·4–17·3)
Data are incidence (95% CI). Incidence data for all NCDs, except 
hypercholesterolaemia and hypertension, are from the Monitoring report 2011.23 
Hypercholesterolaemia and hypertension were calculated from the ATHENA data, 
with the same method as used in the report. NCD=non-communicable disease. 
Table 2: Incidence of newly diagnosed, routinely collected serious 
comorbidities by age group and sex
For the HIV Drug Interaction 
chart see http://www.hiv-
druginteractions.org
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infected patients had been diagnosed with at least one 
cardiovascular disease, 4% with diabetes, and 2% with a 
non-AIDS disease, 4% had diabetes, and 2% had a non-
AIDS malignancy. The model predicts that in 2030, 
78% of patients will have been diagnosed with 
cardiovascular disease, 17% with diabetes, and 17% with 
malignancies.
One of the many consequences of an ageing population 
and increasing burden of NCDs will be an increase in 
polypharmacy. The model projects that in 2030, 54% of 
HIV-infected patients in clinical care will be taking at 
least one other long-term drug aside from their HIV 
drugs (up from 13% in 2010), and 20% of patients will be 
prescribed three or more co-medications (up from 5% in 
2010; ﬁ gure 4).
The increasing burden of polypharmacy will mainly be 
driven by cardiovascular drugs, in turn driven by the 
increasing burden of cardiovascular disease (ﬁ gure 4). In 
the ATHENA cohort in 2010, 9% of HIV-infected patients 
were prescribed cardiovascular drugs. This proportion is 
predicted to increase to 50% in 2030, with patients 
prescribed both antidiabetic drugs and cardiovascular 
drugs expected to increase from 2% in 2010 to 7% in 2030.
The model predicts that the increasing burden of 
polypharmacy and NCDs could cause an increase in 
complications with ﬁ rst-line ART. We predict that the 
proportion of HIV-infected patients on ART who will 
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 Figure 2: Projected age distribution of HIV-infected patients
The red box shows the age distribution of patients on antiretroviral therapy in 
clinical care in the Netherlands in 2010, which matches the data exactly, and the 
blue box shows model output from 2011–30.
2010 2015 2020 2025 2030
0
2000
4000
6000
8000
10 000
12 000
14 000
16 000
Year
N
um
be
r o
f p
eo
pl
e
A
B
3 or more comorbidities
2 comorbidities
1 comorbidity
No comordities
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Pr
op
or
tio
n 
of
 in
di
vi
du
al
s w
ith
 co
m
or
bi
di
tie
s (
%
)
 
HIV-infected 
<4
5 
45
–5
0 
50
–5
5 
55
–6
0 
60
–6
5 
>6
5 
<4
5 
45
–5
0 
50
–5
5 
55
–6
0 
60
–6
5 
>6
5 
HIV-uninfected 
Age group (years)
 Figure 3: Predicted comorbitities
(A) Predicted burden of NCDs in HIV-infected patients between 2010 and 2030 
as simulated by the model. (B) Distribution of the number of NCDs by age group 
for HIV-infected and HIV-uninfected patients in 2030. NCD=non-communicable 
disease.
Hazard ratio (95% CI) Source
Myocardial infarction or stroke if diabetes 2·31 (1·83–2·92) Worm and colleagues 200924
Myocardial infarction or stroke if hypertension 1·26 (0·98–1·62) Worm and colleagues 200924
Myocardial infarction or stroke if 
hypercholesterolaemia
1·41 (1·12–1·76) Worm and colleagues 200924
Chronic kidney disease if diabetes 1·50 (1·05–2·16) Mocroft and colleagues 201025
Chronic kidney disease if hypertension 1·69 (1·26–2·27) Mocroft and colleagues 201025
Hypertension if diabetes 1·40 (1·19–1·64) ATHENA data
Hypercholesterolaemia if diabetes 1·12 (0·968–1·295) ATHENA data
Hypertension if hypercholesterolaemia 1·277 (1·16–1·397) ATHENA data
Hazard ratio gives ratio of risk for an individual developing a disorder in view of another underlying disorder compared 
with patients without another underlying disorder.
Table 3: Association between risk of an individual developing a new disorder, in view of current disorders
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experience drug–drug interactions or contraindications 
with any of the currently recommended ﬁ rst-line regimens 
will increase from 12% in 2010 to 53% in 2030. 
Additionally, 3% of patients in 2030 will be prescribed co-
medication with as yet unknown drug–drug interactions, 
compared with 1% in 2010. Consequently, 40% of HIV-
infected patients in clinical care in the Netherlands could 
experience some form of long-term complication with at 
least one of the currently recommended ﬁ rst-line ART 
regimens, and might need to switch to alternative ART 
regimens. Furthermore, 11% of HIV-infected patients in 
2030 are projected to have potential problems with all of 
the currently recommended ART regimens. These 
complications will mainly be driven by an increase in the 
number of patients with chronic kidney disease (where 
tenofovir is contraindicated) and severe cardio vascular 
disease (where abacavir is contraindicated) and increased 
use of alendronic acid to treat osteoporosis.
Discussion
The proﬁ le of patients in Europe infected with HIV is 
changing and this will have major implications for clinical 
care. In the Netherlands in 2030, almost three-quarters of 
patients on ART will be aged 50 years or older. This 
distribution will result in an increased burden of age-
related NCDs (higher than that of uninfected individuals), 
increased burden of polypharmacy, and an increasing 
proportion of patients who might have potential 
complications with their HIV treatment. Improvements 
achieved in clinical care so far, in terms of mortality,2,26 
better tolerability of antiretroviral drugs and 
immunological and virological recovery of patients on 
ART,1 could potentially be oﬀ set by an ageing HIV-
infected population. We expect other European countries 
with HIV epidemics concentrated in men who have sex 
with men to face broadly similar trends to those we have 
projected for the Netherlands, although these will be 
modiﬁ ed by underlying lifestyle and other factors.
The ageing HIV-infected population will put new 
demands on the health-care systems, which will have 
important implications for the health of HIV-infected 
patients in clinical care.3–5,27 Care management for HIV-
infected individuals will increasingly need to draw on a 
wide range of medical disciplines, including geriatric 
medicine, cardiology, and oncology. Evidence-based changes 
to screening and monitoring protocols for NCDs in HIV-
infected patients will be important to ensure continued 
high-quality care. HIV treatment and other guidelines are 
continuously evolving, and future guidelines will have to 
account for the changing demographics and complex 
changes in patient proﬁ les and needs identiﬁ ed here.
Until recently, the ageing HIV-infected population has 
been largely ignored, with most randomised trials of 
ART excluding older patients or people with comorbid 
disease.3 Consequently, many questions remain,28 includ-
ing those regarding the clinical care of ageing HIV-
infected patients, tolerability of ART in patients with 
multiple morbidities, the eﬀ ect of large pill burden on 
adherence and treatment outcome, pharmacodynamics 
and pharmacokinetics in older patients, and interactions 
between ART and coadministered drugs. Quantiﬁ cation 
of the scale and overall eﬀ ect of this changing demo-
graphy is an important step to tackle this challenge.
New drugs will be needed to fulﬁ l the demand for 
increased numbers of antiretroviral drugs that can safely 
be given alongside co-medications, while maintaining 
high eﬃ  cacy. Anti retroviral drugs with no drug–drug 
interactions with co-medications for the NCDs that will 
increase in prevalence during the next 20 years, including 
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drugs for osteoporosis, cardiovascular diseases, and 
diabetes, will be particularly important. For example, 
nucleoside reverse-transcriptase inhibitors are needed that 
can be used safely in ﬁ rst-line regimens for individuals 
with serious cardiovascular disease and chronic kidney 
disease, such as tenofovir alafenamide, which showed 
signiﬁ cantly reduced toxic eﬀ ects in the liver and bone 
compared with tenofovir disoproxil fumarate in phase 2 
clinical trials.29 In terms of antiretroviral drugs that can be 
used as a third component in combination therapy, need is 
increasing for more antiretroviral drugs with high eﬃ  cacy 
and good safety proﬁ les—such as raltegravir and 
dolutegravir—that can safely be coadministered with co-
medication such as osteoporosis drugs, cardiovascular 
drugs, and sulfonylurea derivatives to treat diabetes. New 
drug development will become increasingly important in 
view of the increasing burden of polypharmacy and a 
falling number of recommended highly eﬀ ective ﬁ rst-line 
HIV-treatment regimen options that can be safely given to 
patients with multiple morbidities.
Our results comparing HIV-infected and HIV-uninfected 
individuals in 2030 mostly accord with those of the AGEhIV 
study,6 largely reproducing the diﬀ erent patterns of NCD 
burden reported for these two populations. However, the 
NCDs studied and diagnostic deﬁ nitions used do diﬀ er 
somewhat between our study and theirs.6 Our predictions 
about age structure are similar in outlook to those reported 
by Jansson and colleagues30 in Australia, who constructed 
an individual-based stochastic geographically referenced 
model of HIV-infected people. They predicted that by 2020, 
44% of HIV-infected people will be aged 55 years or older. 
By contrast, Cysique and colleagues31 estimated that the 
proportion of HIV-infected individuals aged 60 years and 
older in Australia would only increase from 7% to 19% 
between 2009 and 2030. Because of diﬀ erent incidence 
projections, these estimates are lower than were those 
generated by our model (38%), despite similar age 
distributions at the start of the models.31
We believe that our results can be generalised to other 
high-income countries with mature epidemics 
predominantly in male populations and a history of good 
access to HIV care. The exclusion of pregnant women 
restricts the extent to which the results can be extrapolated 
to other populations, especially those in sub-Saharan 
Africa, which have large generalised epidemics. However, 
the trends towards an ageing HIV-infected population that 
are emerging in Australia and Europe, can broadly be 
expected to occur in Africa in the future: Hontelez and 
colleagues32 have predicted that by 2040, the proportion of 
HIV-infected patients aged 50 years or older will be 25% in 
sub-Saharan Africa compared with 73% predicted in the 
Netherlands. The challenges in an African setting will vary 
substantially, especially where health-care systems are 
mainly providing episodic care for acute symptomatic 
conditions or services for maternal and infant health.33,34
The model captures the key factors that aﬀ ect HIV 
clinical care, including major age-related NCDs, their 
common physiological pathways, and treatment. We 
based the parameterisation on the national ATHENA 
cohort, a non-selective dataset of all HIV-infected 
patients in clinical care in the Netherlands. Where the 
data were insuﬃ  cient, we did an in-depth literature 
review, selecting, where possible, data from recent large 
inter national studies. The incorporation of common 
causal pathways allows us to model the natural 
aggregation of NCDs in patients. We did out-of-sample 
model checks that showed that the projections made by 
the model concurred with the ATHENA data, at least in 
the short term (appendix).
Despite these strengths, the model is limited by the 
fact that it does not represent all diseases that aﬀ ect these 
populations. To the extent that NCDs have not been 
included, the model results will be conservative in its 
predictions of multimorbidity and polypharmacy. In 
particular, the model does not include neurocognitive 
disorders. We expect age-related neurocognitive dis-
orders, such as late-onset Alzheimer’s disease and 
Parkinson’s disease to have little eﬀ ect on model 
projections because they are rare, with a mean age of 
onset of about 74 and 61 years, respectively.35,36 However, 
depression is the most prevalent neuropsychiatric 
complication in HIV-infected patients.37 Depression has 
been reported37,38 to reduce drug adherence and quality of 
life while increasing pill burden, drug–drug interactions, 
and mortality. Data for neurocognitive impairment are 
poorly collected in cohort studies but have important 
consequences for treatment outcome. Collection of these 
Panel: Research in Context
Systematic review
We searched PubMed for studies up to Aug 14, 2014, with the terms “HIV” and “ageing” or 
“aging”, and “co-morbidity” or “non-communicable disease”, and “model” or “modelling” 
or “modeling”, in addition to “HIV” and “ageing” or “aging” and “model” or “modelling” or 
“modeling” with no language or date restrictions. We identiﬁ ed no studies that predicted 
the burden of non-communicable diseases, polypharmacy, or drug–drug interactions in 
HIV-infected patients in the future using any of these search terms. We identiﬁ ed several 
studies that predicted the age structure of patients infected with HIV beyond 2010.
In Australia, Jansson and colleagues28 constructed an agent-based stochastic 
geographically referenced model of HIV-infected people, which predicted that by 2020, 
44% of HIV-infected people will be aged 55 years or older. Hontelez and colleagues30 
predicted that in sub-Saharan Africa, this proportion will increase to about 25% by 2040. 
Additionally, Cysique and colleagues29 predicted that the number of HIV-infected patients 
aged 60 years or older in Australia would increase from 7% in 2009 to 19% in 2030, 
paralleled by an increase in the number of patients who will have HIV-associated 
neurocognitive disorders and non-HIV dementia.29
Interpretation
To our knowledge, this is the ﬁ rst model that has quantiﬁ ed burden of disease and 
polypharmacy, in addition to demographic projections for a developed country with an 
ageing epidemic. The model captures the key factors aﬀ ecting clinical care of HIV-infected 
patients, including the major age-related non-communicable diseases, their common 
physiological pathways, and their treatment.
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data should be a priority in the context of the ageing HIV-
infected population. In their model, Cysique and 
colleagues31 further estimated that the number of HIV-
infected individuals with HIV-associated neurocognitive 
disease would increase to 8·5%. Some other NCDs 
might remain undiagnosed or under-reported in obser-
vational cohorts and have therefore not been entered into 
the model. Furthermore, we did not explicitly model 
recurrent events of myocardial infarction or stroke.
In the absence of detailed data for heterogeneity of 
lifestyle factors (eg, diet, smoking, and exercise) or credible 
projections for how the prevalence of these factors will 
change with time, we assumed that their eﬀ ect would be 
uniform in the population and constant with time, as 
already shown in the estimates from ATHENA data. A 
potential consequence of this assumption could be 
overestimation of the proportion of patients who have one 
or more NCDs if risk factors are conﬁ ned to a small 
proportion of the population or the proportion of 
individuals with such risk factors would decline in the 
future. The model does not simulate the eﬀ ect of individual 
antiretroviral drug use on the development of NCDs—eg, 
the reported association of abacavir with cardiovascular 
disease39–41 or the association between speciﬁ c protease 
inhibitors and tenofovir and osteoporosis.13,42 Although 
disease caused by historical use of antiretroviral drugs will 
have been captured in the parameter estimates, we saw no 
evidence that the risk for development of NCDs diﬀ ered 
between cohorts who started ART early (1996–2000) 
compared with those who started more recently (2006–10).
Finally, another aspect of clinical care that is diﬃ  cult to 
represent in a model is the complex, multifactorial nature 
of prescribing practices. Treatment depends on a large 
number of factors, such as patient characteristics, 
compliance, and medical judgments made by clinicians, 
including those based on information and perceptions not 
recorded in patients’ records. By necessity, the model had 
to make several assumptions (for example that prescribing 
co-medication is independent of age), but these should not 
prevent conclusions from being drawn about the long-
term eﬀ ect of polypharmacy. Our model projections rely 
on the assumption that clinical and demographic patterns 
will remain constant in the future. Any changes in clinical 
care, including guidelines recommending earlier 
treatment initiation, new ﬁ rst-line ART with reduced toxic 
eﬀ ect and drug interaction proﬁ les, or aggressive screening 
and monitoring protocols for NCDs and their risk factors, 
could reduce the burden of NCDs. If the future of clinical 
care changes the drivers of increased risk of NCDs in HIV-
positive individuals (ie, inﬂ ammation, immune activation, 
and toxic antiretroviral drugs), the disease burden in future 
cohorts of HIV-infected populations will be more similar 
to that of the HIV-uninfected populations than these 
projections suggest. The model results can be updated if 
new data becomes available on some of these factors.
To our knowledge, this is the ﬁ rst modelling study 
quantifying the burden of age-related NCDs and 
polypharmacy, in addition to demographic projections, for 
a developed country with an ageing epidemic (panel).
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